Žydrūnas Martinėnas, deputy director of Lithuania's State Medicines Control Agency, told BNS Lithuania that the potential risk of the identified impurities is being assessed by the European Medicines Agency.

In his words, there are market alternatives with the same active ingredient to the recalled medications.

"New medications should be prescribed by the doctor," Martinėnas told BNS Lithuania.

The medications might have been contaminated with impurities during the manufacturing process, the Lithuania's State Medicines Control Agency said.